The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
Abstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Items 501–600 of 793
Colson, P., Dhiver, C., Tamalet, C., Delerce, J., Glazunova, O. O., Gaudin, M., Levasseur, A., & Raoult, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-58969-6 · Cited by 7
Self-citationRetractedGut microbiome-immune crosstalk affects progression of cancer
Tilg, H., Schmiderer, A., & Djanani, A. M. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.06.02 · Cited by 8
Intratumoral microbiome composition and its role in tumor recurrence in primary liver cancer
Liu, W., Kuo, H., Tsai, H., Lin, Y., Ruan, J., Lee, C., Sun, H.-Y., Wu, I., & Chang, T. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.11.031 · Cited by 6
Comparative oncology using domesticated dogs and their microbiome
Santiago-Rodríguez, T. M. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1378551 · Cited by 6
“It is known that the microbiota may impact the efficiency of cancer treatments; thus, characterizing microbial communities in association with lymphoma and other types of cancers can also help predict the outcome of therapy (i.e., responders vs. non-responders) (19).”
BackgroundThe microbiome-immune cell interaction network: Advancing tumor immunotherapy
Liu, W., Lan, Z., Lin, Z., Zhao, Y., Lian, J., & Yu, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.009 · Cited by 8
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
Microbiome-mediated regulation of chemoradiotherapy response
Lan, Z., Li, B., Ren, J., Wang, S., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1659467 · Cited by 6
“Lactobacillus acidophilus enhances oxaliplatin-induced DNA lesions by activating macrophage NADPH oxidase while impairing non-homologous end joining repair (74).”
Monger, X. C., Saucier, L., Gilbert, A.-A., & Vincent, A. T. (2022) · MethodsX · doi:10.1016/j.mex.2022.101716 · Cited by 6
Chang, Z., Bo, S., Xiao, Q., Wang, Y., Wu, X., He, Y., Iqbal, M., Ye, Y., & Shang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1055146 · Cited by 6
“Gut microbiota contributes greatly to the host health and nutrient digestion (Coleman et al., 2018; Kumar et al., 2018; Zitvogel et al., 2018; Lei et al., 2021).”
BackgroundResearch Progress in Intestinal Microecology in Pancreatic Cancer Diagnosis and Treatment
Han, Z., Zhang, H., Lu, L., Li, X., Zhang, C., Zhu, J., Li, C., Wang, Q., & Chen, K. (2022) · Journal of Oncology · doi:10.1155/2022/6069403 · Cited by 6
Tumor-resident intracellular bacteria benefit metastasis
Koyama, K., & Inamura, K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6209 · Cited by 7
Factors of faecal microbiota transplantation applied to cancer management
Liu, Y.-H., Chen, J., Chen, X., & Liu, H. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2023.2299724 · Cited by 6
“the composition of the microbiota varies greatly among different hosts, and these variations may be a potential reason for differences in the development of specific diseases and treatment outcomes [22].”
BackgroundGuo, Z., Lei, Y., & Wang, Q. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12692 · Cited by 7
“Future precision medicine strategies may rely on new diagnostic and therapeutic tools for identifying and correcting microbiota deficiencies that affect treatment outcomes (24).”
BackgroundWang, C., Wang, J., Guan, W., & Fei, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01285-6 · Cited by 6
“…of GC and may have an impact on the response to immunotherapy, enhancing the immune response to tumors in a various ways, such as by activating T cells in response to bacterial antigens that may also target tumor antigens and producing metabolites that have systemic effects on the host [37].”
BackgroundSustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab
Stüven, A. K., & Wiedenmann, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26906 · Cited by 6
“As shown for treatment with antibiotics, pretreatment might influence the composition of intestinal microbiota and therefore the outcome of patients treated with pembrolizumab [51, 52].”
BackgroundSannicolo, S., Levra, M. G., Gouëllec, A. L., Aspord, C., Boccard, J., Chaperot, L., Toussaint, B., Moro‐Sibilot, D., Hannani, D., & Toffart, A. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2021.100845 · Cited by 6
Impact of General Factors on Glioma Immunotherapy
Huang, Q., Wang, D., Yao, G., & Wang, H. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.1.3 · Cited by 6
Nandi, S. K., Basu, S., Bhattacharjya, A., Ghosh, R. D., Bose, C. K., Mukhopadhyay, S., & Bhattacharya, R. K. (2022) · Nutrition · doi:10.1016/j.nut.2022.111787 · Cited by 6
The gut microbiome and dietary metabolites in the treatment of renal cell carcinoma
Zugman, M., Wong, M. H., Jaime‐Casas, S., & Pal, S. K. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.07.003 · Cited by 6
The Gut Microbiome in Inflammatory Bowel Disease
Lavelle, A., & Sokol, H. (2019) · Springer eBooks · doi:10.1007/978-3-030-28703-0_16 · Cited by 7
Wang, J., Reyes‐Gibby, C. C., & Shete, S. S. (2020) · Statistics in Biosciences · doi:10.1007/s12561-020-09295-y · Cited by 6
Ferreira, A., Neves, M. T., Baleiras, A., Malheiro, M., & Martins, A. (2022) · Cureus · doi:10.7759/cureus.32586 · Cited by 7
“Moreover, new evidence suggests that it influences oncogenesis and therapeutic outcomes in cancer by regulating local and systemic antitumor immunity [2].”
BackgroundRole of gut microbiota in tumorigenesis and antitumoral therapies: an updated review
Singhal, S., Bhadana, R., Jain, B. P., Gautam, A., Pandey, S., & Rani, V. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2166268 · Cited by 7
“Probiotics are administered to cancer patients to repopulate the gut microbiota of patients to maintain their functionality (Zitvogel et al., 2018).”
An association between the gut microbiota and immune cell dynamics in humansPreprint
Schlüter, J., Peled, J. U., Taylor, B. P., Smith, M. M., Markey, K. A., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/618256 · Cited by 6
Parasympathetic influences in cancer pathogenesis: further insights
Kumaria, A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02523-3 · Cited by 6
Zhao, M., Tian, J., Hou, W., Yin, L., & Li, W. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1416385 · Cited by 6
The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment
Distante, A., Garino, D., Cerrato, C., Pérez‐Ardavín, J., Quereda-Flores, F., Lopetuso, L. R., & Mir, M. C. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01028-w · Cited by 6
“Additionally, microbial dysbiosis has been linked to immune dysfunction, which may explain why immunotherapies fail in most metastatic castration resistant prostate cancers [11, 12].”
Yang, Z., Liang, L., Li, X., Peng, X., Qian, X., Huang, Z., Wang, X., Hu, Q., & Fu, X. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117711 · Cited by 7
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Wen, X., Ye, X., Yang, X., RuJin, J., Qian, C., & Wang, X. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02995-5 · Cited by 5
“Through (1) the activation of T-cell responses, (2) the recruitment of a pattern recognition receptor with proinflammatory characteristics, or (3) the regulation of specific metabolites, which can stimulate T-cell receptors, the intestinal microbiome affects the antitumor immunological response during malignancy [21].”
BackgroundWei, J., Guo, X., Yang, X., Liu, J., Duan, Q., Tan, Y., Zhang, Q., Sun, T., Qi, C., Li, X., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0929 · Cited by 5
Nourishing the gut: the impact of diet on host–gut microbiota interaction
Masi, D., Roy, T. L., Adriouch, S., & Clément, K. (2024) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001009 · Cited by 10
Li, J., Li, J., Liu, Y., Zeng, J., Liu, Y., & Wu, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1423951 · Cited by 5
Dorobisz, K., Dorobisz, T. A., & Pazdro-Zastawny, K. (2024) · Cancers · doi:10.3390/cancers16193416 · Cited by 5
“Disturbance of the immune system by the microbiome consists in the induction of inflammation with simultaneous immunosuppressive effects [49].”
BackgroundMahooti, M., Safaei, F., Firuzpour, F., Abdolalipour, E., Zare, D., Sanami, S., Safavi, M., & Mirdamadi, S. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01855-2 · Cited by 8
“In a similar study, the use of probiotics reduced the adverse effects of chemotherapy on the intestinal mucosa, which can lead to dysbiosis and may be effectively mitigated (Zitvogel et al. (2018)).”
Applications and Achievements of Single-Cell Sequencing in Gastrointestinal Cancer
Xie, Z., Li, J., Huang, P., Zhang, Y., Yang, J., Liu, K., & Jiang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905571 · Cited by 6
Kudo‐Saito, C., Boku, N., Hirano, H., & Shoji, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009701 · Cited by 5
Zhu, W., Li, J., Chen, Y., Liu, Z., Zhang, Q., & Kang, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109768 · Cited by 5
Potential predictors of immunotherapy in small cell lung cancer
Skopelidou, V., Strakoš, J., Škarda, J., Raška, M., & Kafkova, L. R. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611086 · Cited by 7
Microbiota, mucosal immunity, and Colon cancer
Drewes, J. L., Domingue, J. C., & Housseau, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819672-4.00008-8 · Cited by 5
Wojciechowski, S., Majchrzak-Gorecka, M., Biernat, P., Odrzywołek, K., Pruss, Ł., Zych, K., Majta, J., & Milanowska, K. (2022) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2022.151560 · Cited by 6
Cavarretta, I. T. R., Mancini, N., & Salonia, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.07.009 · Cited by 5
Liang, M., Liu, Z., Zhang, R., Yang, J., Wang, X.-W., & Zhang, N. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1619323 · Cited by 4
Ni, D., Xing, J., Niu, G., Qiu, J., Wei, G., Chen, G., Zhou, Q., & Yin, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1757516 · Cited by 5
Hacıoğlu, Ö. (2026) · Progress in molecular and subcellular biology · doi:10.1007/978-3-032-11438-9_9 · Cited by 4
Sugumar, K., Alabd, A., Alabd, A., Hue, J. J., Lyons, J., Fields, S., Wainberg, Z. A., Zheng, L., Coogle, B., Kasi, A., et al. (2025) · Oncotarget · doi:10.18632/oncotarget.28739 · Cited by 5
Ebrahimi, R., Nejad, S. S., Fekri, M., & Nejadghaderi, S. A. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100420 · Cited by 12
Sawamura, H., Taniguchi, K., Ikeda, Y., Tsuji, A., Kitagishi, Y., & Matsuda, S. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.57 · Cited by 4
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490-en · Cited by 6
Xu, J., Tian, Y., Hu, D., Xi, Y., & Yang, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.85 · Cited by 5
Liu, Y., Lin, X., Hu, S., Zheng, E., Ye, Y., Xu, B., & Wu, L.-C. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002836 · Cited by 4
“The exploration of the intestinal microbiota offers new diagnostic modalities and therapeutic strategies across diverse clinical conditions [14,15].”
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Un tour d’horizon du développement de biomarqueurs pour les anticorps PD-1 et PD-L1 en cancérologie
Chaput, L., & Jordheim, L. P. (2021) · Therapies · doi:10.1016/j.therap.2021.06.005 · Cited by 4
Thomas, A. R., Eyada, M., Kono, M., Varatharajalu, K., Lu, Y., Xu, G., Panneerselvam, K., Shatila, M., Altan, M., Wang, J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04405-3 · Cited by 4
“Gut dysbiosis has been postulated as one of the mechanisms behind ICI-induced colitis, and restoration of healthy microbiota can improve refractory ICI-induced colitis (Wang et al. 2018a, b, c; Zitvogel et al. 2018).”
BackgroundPaden, H., Kurbatfinski, N., Poelstra, J. W., Ormiston, K., Orchard, T., & Ilić, S. (2023) · Nutrients · doi:10.3390/nu15030724 · Cited by 4
“Both the composition of the intestinal microbial populations and their diversity are vital to maintaining patient health [8].”
Microbiota Manipulation as an Emerging Concept in Cancer Therapy
Spalinger, M. R., & Scharl, M. M. (2023) · Visceral Medicine · doi:10.1159/000534810 · Cited by 4
“…generally associated with health, such as Clostridiales, Ruminococcaecae , Fae-calibacterium spp., Akkermansia muciniphila , B. fragilis , and Bi fi dobacteria were found to be increased in the intestine of melanoma patients who responded well to ICI therapy when compared to non-responders [17, 23].”
BackgroundSIU–ICUD consultation on bladder cancer: basic science
McConkey, D. J., & Lerner, S. P. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2594-y · Cited by 5
Are we there yet? Gut microbiota for cancer diagnosis, prognosis and treatment
Ordóñez, C., Zurita, S., Ramírez, G., Cordeiro, F. B., García, K., Garaicoa, F. H., Orellana‐Manzano, A., Onofre, L. A. S., Pogo, J., & Carvajal‐Aldaz, D. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152376 · Cited by 3
Microbiome in Neuroblastoma: A Virgin Island in the World of Onco-Microbiome
Giri, A. K., Subramanian, P., Periyasamy, L., Aravindan, S., & Aravindan, N. (2025) · Cells · doi:10.3390/cells14151218 · Cited by 3
“These probiotics increase regulatory T cell (Treg) function, facilitating immunological tolerance and decreasing excessive immune activation linked to tumor growth [242].”
Maqrashi, Z. A. A. A., Bradbury, M., Chan, S. W. S., AlHarbi, Y., Fazzari, F. G. T., Gabara, A., Faisal, H., Sadeghian, S., Pond, G. R., Meyers, B. M., et al. (2025) · Future Science OA · doi:10.1080/20565623.2025.2552067 · Cited by 3
The microbiome shaping cancer development, progression, and therapeutic response
Salihoğlu, R. (2025) · Physiological Genomics · doi:10.1152/physiolgenomics.00091.2025 · Cited by 3
Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies
Ouyang, D., Chen, R., Xie, H., Yang, X., Li, Q., & Chen, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.007 · Cited by 3
Honcharyuk, I., Caridi, B., Pinco, P., Ferri, S., Giani, A. D., Baeri, A., Amoroso, C., Massironi, S., & Facciotti, F. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2602537 · Cited by 3
“Generally, microorganisms associated with health (Clostridiales, Ruminococcaceae, Akkermansia muciniphila , B. fragilis , and Bifidobacteria) or immunogenicity (Enterococci, Collinsella , and Alistipes ) seem to be enriched in responding patients [94].”
The convergence of synthetic biology and metagenomics: Current advances and future perspectives
Maqbool, M., Haque, E., Thacharodi, A., Meenatchi, R., Arafath, A. Y., Fathima, S. A., Genevieve, K. K., Singh, T., Rajalakshmi, D., Nisha, K., et al. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102506 · Cited by 3
Sharma, S. R. K., Saha, S., Arora, S., Ahlawa, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100012 · Cited by 3
Huang, R., Yao, Y., Tong, X., Wang, L., Qian, W., Lu, J., Zhang, W., Liu, Y., Wang, S., Xian, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00135-23 · Cited by 3
MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer
Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G. M., Keulers, T. G., Wieten, L., & Rouschop, K. M. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316716 · Cited by 4
“…representative of three or more independent experiments and values are expressed as mean ± SD. https://doi.org/10.1371/journal.pone.0316716.g004 associated with ICI response in NSCLC patients and administration of antibiotics prior to immune therapy reduces cancer immunotherapy efficacy [90,91].”
InfluentialThe microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes
Bailey, A., Leuther, K. K., & Robinson, L. A. (2025) · Frontiers in Microbiomes · doi:10.3389/frmbi.2025.1606551 · Cited by 5
“Additionally, a number of studies have shown that antibiotic misuse may not only aggravate the side effects from the administration of antineoplastic drugs, but they may potentially cause severe systemic adverse events (Zitvogel et al., 2018).”
Elkourashy, S. A., Abu-El-Ruz, R., Askar, M. Z., Hamdan, A., & Zughaier, S. M. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101341 · Cited by 3
Gut Check: In Vitro Diagnostics for Gut Microbiome Analysis
Hernandez, D. R. (2019) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2019.03.005 · Cited by 3
Microbiome Diagnostics and Interventions in Health and Disease
Dasgupta, N., Srivastava, A., Rao, A., Murugkar, V., Shroff, R., & Das, G. (2021) · Springer eBooks · doi:10.1007/978-981-16-3156-6_10 · Cited by 4
Cancer du rein métastatique : gestion des toxicités des combinaisons
Joly, F., Michot, J., Dourthe, L. M., Fléchon, A., Mahammedi, H., Maillet, D., Mouillet, G., Pouessel, D., Rolland, F., Topart, D., et al. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.04.019 · Cited by 4
Human microbiota: role in cancer progression and therapy
Rais, A., Chand, P., Malik, M., & Prasad, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96128-8.00006-7 · Cited by 3
Importance of Gut Microbiome-Based Therapeutics in Cancer Treatment
Bazaz, M. R., Rahman, Z., Qadir, I., Pasam, T., & Dandekar, M. P. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-981-19-9786-0_24 · Cited by 3
Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer
Marzhoseyni, Z., Shaghaghi, Z., Alvandi, M., & Shirvani, M. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096274860231111210214 · Cited by 4
Felchle, H., Gissibl, J., Rotgerink, L. L., Nefzger, S. M., Walther, C. N., Timnik, V. R., Combs, S. E., & Fischer, J. C. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100758 · Cited by 5
“It is therefore explicitly speculated that these metabolites might also immunomodulate response rates to ICI therapy [24]; a speculation that is corroborated by a recent study reporting oral supplementation of DAT to boost cancer immunotherapy with anti-CTLA4 which was dependent on IFN-I signaling…”
Molecular diagnostics in oncology: new trends
Имянитов, Е. Н. (2020) · Medical academic journal · doi:10.17816/maj19281 · Cited by 3
Phages Needed against Resistant Bacteria
Moelling, K. (2020) · Viruses · doi:10.3390/v12070743 · Cited by 4
“Certain bacteria are required for successful immunotherapy [26].”
BackgroundFuture of lung cancer treatment
Petruzelka, L. B., Špaček, J., & Křížová, Ľ. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s71 · Cited by 5
A bacterium-derived, cancer-associated immunopeptidome
Perreault, C., Thibault, P., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1918373 · Cited by 3
Self-citationGuo, J., Huang, T., & Zhou, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-02172-4 · Cited by 3
“Beyond metabolic changes, microorganism-associated molecular patterns (MAMPs) that mediate inflammatory responses are also considered potential mechanisms for tumorigenesis, as GM can drive inflammation through pro-inflammatory cytokines such as IL-17, IL-23, TNF-α, and IFNγ [28–30].”
Chae, S., Chae, S., Kang, T. G., Kim, S. J., & Choi, A. (2025) · Bioengineering · doi:10.3390/bioengineering12040367 · Cited by 3
“Integer (discrete) [1, 6] Epoch Integer (discrete) [5, 20] Momentum Real (continuous) [0.7, 0.99] After completing the Bayesian optimization process, the optimal design variables were extracted, then used to train the model.”
InfluentialMetagenome and metabolome study on inhaled corticosteroids in asthma patients with side effects
Goryanin, I., Sorokin, A., Seitov, M., Искаков, М. Б., Iskakov, M., Goryanin, I., & Osmonov, B. (2025) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2024-0062 · Cited by 2
Jin, P., Ji, X., Bai, J., Su, W., Ke, B., Liu, Y., & Wang, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622959 · Cited by 3
Murat-Ringot, A., Lan, R., Goetz, E., Basbous, L., Charreyre, M., & Carrouel, F. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-10049-z · Cited by 3
“Given that oncologic treatments often disrupt microbial balance, dietary strategies centered on whole grain, fiber-rich foods may confer both digestive and immunological benefits [52, 53].”
Implementing gut microbiota, ROS, and SCF modulation in cancer care: Research into practice
Jana, K., Ghosh, S., Debnath, B., Rai, V. K., Dash, P., Das, C., Rout, S. K., Kar, B., Ghosh, G., & Rath, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33459-7.00013-2 · Cited by 2
Advanced computational analysis in metagenomic studies to support precision medicine
Piccinno, G., & Asnicar, F. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.02.018 · Cited by 2
Su, X., Li, A., Liu, J., Guo, Y., Yu, H., Yu, J., Wang, R., Garza, D. R., Qu, J., Wen, B., et al. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128539 · Cited by 3
Alawad, D. M., Fertel, M., & Hicks, C. (2026) · Cancers · doi:10.3390/cancers18101503 · Cited by 2
“Multi-omics machine learning approaches integrating host transcriptomics with microbiome-derived metagenomic and metabolomic data have enabled the identification of composite biomarkers that capture both host and microbial contributions to disease [104].”
Probiotics Cancer Interaction, Prevention, and Therapy
Saebi, M., Barjasteh, A. H., Mahmoudi, M., Kheder, R. K., Ramazanpour, S., Ebadpour, N., Fadaee, A., & Esmaeili, S. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70435 · Cited by 2
Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer
Procopciuc, L. M., Hangan, A. C., & Lucaciu, R. L. (2026) · Nutrients · doi:10.3390/nu18101591 · Cited by 3
“These effects collectively contribute to restoring immune homeostasis and reducing tumor-promoting inflammation [54,71,95].”
Yang, L., Li, Z. Y., Li, Y., Zhang, Q., & Zhang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1791276 · Cited by 2
“Immune checkpoint inhibitors (ICIs), represented by anti – PD-1 antibodies ( a PD-1), have achieved a major breakthrough in solid tumor therapy by blocking the PD-1/PD-L1 pathway and relieving T-cell immunosuppression (4, 5).”
Valaei, A., Zahmatkesh, N., Aghaei, R., Maleki, M., Meskini, M., & Siadat, S. D. (2026) · New Microbes and New Infections · doi:10.1016/j.nmni.2026.101805 · Cited by 2
“Such “ next-generation ” probiotics could be targeted to address deficiencies in a patient's specific microbiome and immune function, or to increase drug metabolism [101].”
InfluentialVaaben, T. H., Lützhøft, D. O., Hedin, K. A., Ahonen, L. L., Vazquez-Uribe, R., & Sommer, M. O. A. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2690687 · Cited by 2
The Dual Role of the Gut Microbiota in Cancer Chemoresistance
Tahmasebi, H., Bahar, A., Khazaei, M., & Arabestani, M. R. (2026) · MicrobiologyOpen · doi:10.1002/mbo3.70357 · Cited by 2
“…microbiome (GM) (which is defined as the many trillions of microorganisms that are colonizing the human gastrointestinal tract) plays an essential role in determining how well a patient responds to cancer treatment and their overall clinical outcome (Roy and Trinchieri 2017; Zitvogel et al. 2018).”
Cho, U., Pu, J., Sharma, A., Song, J., You, J. H., Kim, Y., Im, P. W., Park, H. W., Moon, H. E., Myeong, H. S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02736-0 · Cited by 2
“Preclinical studies have demonstrated that nanoparticles delivering microbial metabolites can modulate gut immune homeostasis and enhance checkpoint inhibitor activity [376].”
Lotfi, E., & Golab, F. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2725033 · Cited by 2
Cancer in 2019 – Progress and Challenges – A Perspective
Chng, W. J. (2019) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v48n2p45 · Cited by 2
Héry-Arnaud, G. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30356-7 · Cited by 2
Measurement Method of Akkermansia Muciniphila by Graphene-Based Transistor for Diseases Diagnosis
Li, G., Lu, Z., Luan, X., Wang, Z., Liu, F., & Liu, L. (2021) · IEEE Transactions on Nanotechnology · doi:10.1109/tnano.2021.3072312 · Cited by 2
“muciniphila is closely related to the healthy host and its concentration is inversely correlated with many diseases, such as, diet-induced obesity [4], diabetes mellitus [5], gut barrier dysfunction [6], atherosclerosis lesions [7], and cancer immunotherapy [8].”
Background
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.